Defence Therapeutics (HAM:DTC) ROCE %: -264.39% (As of Mar. 2026)


HAM:DTC Defence Therapeutics Inc HAM:DTC
27 GF Score
Price €0.29
! 1 Warning Sign
View Full Analysis

What is Defence Therapeutics ROCE %?

Defence Therapeutics HAM:DTC -0.34% 27 ROCE % is -264.39% as of Mar. 2026. GuruFocus rates HAM:DTC with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Defence Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -264.39%.

Defence Therapeutics  (HAM:DTC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Defence Therapeutics ROCE % Related Terms

Defence Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Defence Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics ROCE % Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial -78.48 -315.37 -455.48 -1,731.14 0.00

Defence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -52,600.00 -2,015.79 -4,207.23 -264.39
HAM:DTC
27GF Score
Defence Therapeutics Inc HAM:DTC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Defence Therapeutics ROCE % Calculation

Defence Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-2.03/( ( (0.324 - 1.623) + (1.048 - 0.899) )/ 2 )
=-2.03/( (-1.299+0.149)/ 2 )
=-2.03/-0.575
=353.04 %

Defence Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-7.276/( ( (0.847 - 0.684) + (5.955 - 0.614) )/ 2 )
=-7.276/( ( 0.163 + 5.341 )/ 2 )
=-7.276/2.752
=-264.39 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -264.39% mean?
Defence Therapeutics (HAM:DTC) has a ROCE % of -264.39% as of Mar. 2026.
Is Defence Therapeutics' ROCE % too high?
Defence Therapeutics' current ROCE % is -264.39%. Overall, Defence Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' ROCE % compare to VRTX and REGN?
Defence Therapeutics' ROCE % of -264.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Defence Therapeutics's current ROCE % is -264.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (HAM:DTC) has a current ROCE % of -264.39%. The current ROCE % is -264.39%. Defence Therapeutics' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Defence Therapeutics (HAM:DTC), the current ROCE % is -264.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Defence Therapeutics Business Description

Address 7171 Frederick Banting Street, Montreal, QC, CAN, H4S 1Z9
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
27GF Score

Get the complete analysis for HAM:DTC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price